Viatris, Inc. recalls
4 notices naming Viatris, Inc. as the recalling firm, since December 18, 2024. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Viatris, Inc.: Telmisartan and Amlodipine
Hazard (FDA): Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
FDAMedicines
Viatris Inc: Cardura XL and 1 more
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
FDAMedicines
Potency
Viatris Inc: Levothyroxine Sodium Tablets USP and 10 more
Hazard (FDA): Superpotent Drug and Subpotent Drug: potency failures obtained
FDAMedicines